Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766842 | 0.91 | — | — | |
| SCHEMBL2197027 | 0.82 | — | — | |
| SCHEMBL5378435 | 0.81 | — | — | |
| SCHEMBL28224591 | 0.77 | CYP1A2 (0.43) | ALDH1A1DAOHPGDKDM1AMAOA | |
| SCHEMBL21305354 | 0.77 | SIGMAR1 (0.40) | ALDH1A1DAOKDM1AMAOAMAOB | |
| SCHEMBL9559079 | 0.77 | ESR2 (0.50) | ESR2GBA1HPGD | |
| SCHEMBL79061 | 0.77 | — | — | |
| SCHEMBL80485 | 0.77 | — | — | |
| SCHEMBL968476 | 0.76 | GBA1 (0.38) | GBA1DAOHPGDKDM1AMAOA | |
| SCHEMBL766836 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| CN-108112251-B | NRF2 modulators | 葛兰素史克知识产权发展有限公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20200079759-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| EP-3307739-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016202253-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179187-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | ESR2 76/4885GBA1 3986/4885ALDH1A1 609/4885 |
| US-10604509-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | ESR2 76/4885GBA1 3986/4885ALDH1A1 609/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | ESR2 67/4885GBA1 3888/4885ALDH1A1 621/4885 |
| US-20200079759-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | ESR2 67/4885GBA1 3888/4885ALDH1A1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.